|Bid||34.50 x 1800|
|Ask||36.30 x 900|
|Day's Range||35.20 - 36.40|
|52 Week Range||16.10 - 38.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Orgenesis (ORGS) is an underfollowed player in the biotech sector, but with growing revenue and high-profile clients and partners. Most recently, a prestigious healthcare institute Great Point Partners invested up to $25 million directly in their subsidiary and is acting as a key advisor for their global business expansion. Fundamentals are looking good at ORGS as revenue climbed 73% in fiscal Q2, over the year-ago period.
Novocure (NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
Novocure (NVCR) has announced an addition to its board of directors. Jeryl (Jeri) Hilleman, an experienced executive leader, was elected to Novocure’s board in July 2018. “We are extremely pleased to welcome Jeri to our board of directors,” said Bill Doyle, Novocure’s Executive Chairman.
Novocure (NVCR) announced today that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference
The IEEE Engineering in Medicine and Biology Society’s 40th International Conference is the first conference in which a scientific track will be devoted to Tumor Treating Fields, i
On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), NuVasive Inc. (NASDAQ: NUVA), and Stryker Corp. (NYSE: SYK).
Novocure (NVCR) announced today that Pritesh Shah has been appointed as Novocure’s Chief Commercial Officer, reporting to Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah will be responsible for the development and execution of Novocure’s commercialization strategy worldwide, and for overseeing Novocure’s international business units.
Novocure announced today that it will report financial results for the second quarter 2018 on Thursday, July 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2018, at 8 a.m.
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
Novocure (NVCR) will present today for the first time the design of its phase 3 pivotal trial of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer.
Dr. David T. Hung and Sherilyn D. McCoy, both experienced executive leaders, were elected to Novocure’s board at the annual general meeting of shareholders on May 31. Gert Lennart Perlhagen is retiring from the board after 15 years of service. “We are extremely pleased to welcome David and Sheri to our board,” said Bill Doyle, Novocure’s Executive Chairman.
WallStEquities.com has selected the following Medical Appliances and Equipment stocks for review this morning: Lantheus Holdings Inc. (NASDAQ: LNTH), Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), and NuVasive Inc. (NASDAQ: NUVA). North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s shares gained slightly by 0.35%, closing Wednesday's trading session at $14.20.
Novocure today reported financial results for the quarter and year ended March 31, 2018, highlighting year-over-year growth in active patients and net revenues. Novocure is a global oncology company developing a proprietary platform called Tumor Treating Fields for the treatment of solid tumor cancers.
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 26, 2018 at 8:00 AM Eastern Time. To listen ...
Stock Monitor: Neovasc Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
Novocure announced today positive top-line results from its STELLAR phase 2 pilot trial in mesothelioma demonstrating clinically meaningful improvements in overall survival and progression free survival among patients who received Tumor Treating Fields plus standard of care chemotherapy, pemetrexed and cisplatin or carboplatin, compared to historical control data of patients who received standard of ...
Novocure announced today that new data on Tumor Treating Fields will be presented at the American Association for Cancer Research Annual Meeting 2018, which will be held April 14 through April 18, in Chicago.
Novocure announced today that it will report financial results for the first quarter 2018 on Thursday, April 26, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2018, at 8 a.m.
Novocure announced today that the National Comprehensive Cancer Network has updated its clinical practice guidelines to recommend Optune® in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma in its globally recognized Clinical Practice Guidelines in Oncology for Central Nervous System Cancers.
Stock Monitor: CryoLife Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR ). If you want access ...
Novocure announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018, April 14 through April 18, in Chicago.